kabutan

Veritas In Silico Inc.(130A) Summary

130A
TSE Growth
Veritas In Silico Inc.
466
JPY
-7
(-1.48%)
Apr 30, 9:47 am JST
2.90
USD
Apr 29, 8:47 pm EDT
Result
PTS
outside of trading hours
466.4
Apr 30, 9:48 am JST
Summary Chart Historical News Financial Result
PER
PBR
1.70
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
478 JPY 2.98 USD
Previous Close Apr 28
473 JPY 2.97 USD
High Apr 30, 9:00 am
478 JPY 2.98 USD
Low Apr 30, 9:30 am
463 JPY 2.89 USD
Volume
6,100
Trading Value
3.00M JPY 0.02M USD
VWAP
469.97 JPY 2.94 USD
Minimum Trading Value
46,600 JPY 290 USD
Market Cap
3.02B JPY 0.02B USD
Number of Trades
17
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Slightly High
1-Year Average
415
1-Year High Jul 31, 2025
10,270
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 356,200
Apr 17, 2026 0 358,600
Apr 10, 2026 1,900 349,400 183.89
Apr 3, 2026 0 341,300
Mar 27, 2026 0 344,200
Company Profile
Veritas In Silico operates a platform business for small molecule and nucleic acid drug discovery targeting mRNA.
Sector
Pharmaceuticals
Veritas In Silico Inc. is a Japan-based bio-pharmaceutical company. The company develops a platform for small molecule and nucleic acid drug discovery, specializing in targeting mRNA. It focuses on diseases that cannot be addressed by conventional protein-targeted drug discovery approaches. Using their proprietary in silico RNA structure analysis technology, Veritas In Silico has realized a drug discovery approach that targets partial structures on mRNA. This enables the creation of pharmaceuticals that address unmet medical needs. The company collaborates with multiple pharmaceutical companies, promoting joint research based on their drug discovery platform "ibVIS". By targeting mRNA, Veritas In Silico aims to open up new possibilities in the field of drug discovery and development.